Fig. 2.

Correlation of the tumor HLA-I loss with the reduced mRNA expression of B2M, APM molecules, IRF-1 and NRLC5 in two groups of PC versus control BH (C). Tumor group 1—total HLA loss (combined negative and heterogeneous tumors); and group 2—other types of HLA alterations (locus or allelic losses). Statistically significant decrease in the expression of B2M (p = 0.046), tapasin (p = 0.003), NLRC5 (p = 0.001) and TAP2 (p = 0.05) was found in tumors with total HLA-I loss (group 1). In addition, mRNA expression levels of NLRC5 (p = 0.003) and tapasin (p = 0.003) were also significantly lower in group 2 than in control. *Statistically significant difference compared to control